Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters
- 作者: Zabotina T.1, Korotkova O.1, Chertkova A.1, Zakharova E.1, Tabakov D.1, Dzhgamadze N.1, Savostikova M.1, Artamonova E.1, Khailenko V.1, Kovalenko E.1, Kadagidze Z.1
-
隶属关系:
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- 期: 卷 166, 编号 2 (2018)
- 页面: 241-244
- 栏目: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/240929
- DOI: https://doi.org/10.1007/s10517-018-4323-3
- ID: 240929
如何引用文章
详细
In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16+ lymphocytes and a negative correlation of this parameter with the number of regulatory CD4+CD25+CD127— cells and proliferative activity of Ki-67 tumor cells were revealed. Higher level of Ki-67 was associated with reduced number of effector lymphocytes (CD8+ and CD16+) and elevated content of regulatory CD8+CD11b—CD28— T cells. The absence of expression of estrogen receptors was associated with reduced cytotoxic potential of CD8+ T cell in comparison with ER+ breast cancer. The percentage of CD8+ lymphocytes (CD3+CD8+ and CD8+CD11b+CD28+) among lymphocytes infiltrating the tumor was higher in PR+ breast cancer than in PR— tumors. With increasing the tumor load, the number of lymphocytes expressing CD16 marker and their cytotoxic potential decreased.
作者简介
T. Zabotina
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
编辑信件的主要联系方式.
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
O. Korotkova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
A. Chertkova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
E. Zakharova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
D. Tabakov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
N. Dzhgamadze
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
M. Savostikova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
E. Artamonova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
V. Khailenko
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
E. Kovalenko
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
Z. Kadagidze
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
俄罗斯联邦, Moscow
![](/img/style/loading.gif)